At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REGN Regeneron Pharmaceuticals
Post-Mkt 10-07 18:12:50 EDT
742.12
+3.40
+0.46%
盘后742.12
+0.000.00%
17:40 EDT
High753.68Low734.18Vol626.39K
Open738.05D1 Closing738.72Amplitude2.64%
Mkt Cap76.40BTradable Cap73.38BTotal Shares102.95M
T/O466.02MT/O Rate0.63%Tradable Shares98.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley
Dow Jones  ·  10-07 23:05
Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758
MT Newswires Live  ·  10-07 20:58
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758
Why Vaxcyte Chose A 1.5% Convertible
Macro World​  ·  10-07 14:39
Why Vaxcyte Chose A 1.5% Convertible
Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing
THOMSON REUTERS  ·  10-06 19:52
Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing
Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing
THOMSON REUTERS  ·  10-06 19:52
Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing
Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026
Reuters  ·  10-06 19:02
Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026
JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating
MT Newswires Live  ·  10-06 18:52
JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating
Sanofi Can Move Forward to Pursue Deals
Dow Jones  ·  10-06 15:10
Sanofi Can Move Forward to Pursue Deals
From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run
Bellwether Stocks Movement  ·  10-06 10:42
From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run
Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors
Dow Jones  ·  10-06 04:43
Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors
One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet
Bellwether Stocks Movement  ·  10-05 15:29
One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet
Merck Doubled Off Its Lows — And Analysts Still See More Room
Bellwether Stocks Movement  ·  10-05 14:41
Merck Doubled Off Its Lows — And Analysts Still See More Room
CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2
Bellwether Stocks Movement  ·  10-05 10:38
CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2
Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs
Macro World​  ·  10-03
Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs
23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook
Bellwether Stocks Movement  ·  10-03
23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook
Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating
MT Newswires Live  ·  10-02
Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
TIPRANKS  ·  10-02
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
Piper Sandler Remains a Buy on Regeneron (REGN)
TIPRANKS  ·  10-02
Piper Sandler Remains a Buy on Regeneron (REGN)
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals
Dow Jones  ·  10-02
Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Introduction

Company Name.
Regeneron Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Issue price:
--